A prognostic gene expression index in ovarian cancer—validation across different independent data sets
暂无分享,去创建一个
W. Weichert | C. Denkert | M. Dietel | B. Györffy | J. Budczies | R. Zeillinger | S. Darb-Esfahani | A. Noske | J. Sehouli | B. Müller | D. Könsgen | A. Buckendahl | H. Lage | Balázs Győrffy
[1] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[2] R. Barakat,et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. , 2008, Gynecologic oncology.
[3] S. Rubin,et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Dietel,et al. A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma , 2007, International Journal of Gynecologic Cancer.
[5] C Hill,et al. Interpretation of microarray data in cancer , 2007, British Journal of Cancer.
[6] Anil Potti,et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Salit,et al. Transcript-based redefinition of grouped oligonucleotide probe sets using AceView: High-resolution annotation for microarrays , 2007, BMC Bioinformatics.
[8] D. Levine,et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? , 2007, Gynecologic oncology.
[9] D. Levine,et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) , 2006 .
[10] L. V. van't Veer,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.
[11] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Monzon. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .
[13] R. Myers,et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.
[14] M. West,et al. Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.
[15] Stefan Michiels,et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.
[16] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[17] Marie Joseph,et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Tibshirani,et al. Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.
[19] W. Lichtenegger,et al. „IMO” - Intraoperatives Mapping des Ovarialkarzinoms , 2003 .
[20] W. Lichtenegger,et al. ["IMO"--intraoperative mapping of ovarian cancer]. , 2003, Zentralblatt fur Gynakologie.
[21] M. Gore,et al. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.
[22] B. Karlan,et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. , 1999, Gynecologic oncology.